Pazopanib

4 trials 1 recruiting LOncology

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

2 Completed trials

4 Sponsors

5 Countries

Phase III

Phase I/II

Phase III: 3 Phase I/II: 1

Oversight events:

4 temporary halts across 2 trials

View oversight register →

Indications tested

Dedifferentiated liposarcoma 1 Round cell liposarcoma 1 Pleomorphic liposarcoma 1 Myxoid liposarcoma 1 Metastatic renal cell carcinoma 1

Sponsors using this IMP

Centre Hospitalier Universitaire De Bordeaux 1 Centre Leon Berard 1 Incyte Corp. 1 Intensity Therapeutics Inc. 1

All trials

4 total

A study to investigate efficacy and safety of INT230-6 compared with US standard of care in participants aged ≥ 18 years old with metastatic… Recruiting

2024-512423-36-00 Phase III 5 countries Intensity Therapeutics Inc.
Spartalizumab and low-dose PAzopanib in Refractory or Relapsed solid TumOrs of pediatric and adults SPARTO Halted

2024-513535-24-00 Phase I/II 1 country Centre Hospitalier Universitaire De Bordeaux
RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in pa… Ended

2024-513982-38-00 Phase III 1 country Centre Leon Berard
Pembrolizumab (MK-3475) plus Epacadostat vs SoC in mRCC Ended

2024-512016-22-00 Phase III 1 country Incyte Corp.

Showing 1–4 of 4 trials

← All drugs A–Z